We may from time to time supplement our internal product development initiatives with promising opportunities from other companies, institutions or individuals. We intend to be opportunistic in evaluating in-licensing opportunities with a preference for finding products or product candidates that can improve patient care and create value without significantly distracting from our current product pursuits. In evaluating product opportunities, we give priority to opportunities that are potentially synergistic with our internal R&D projects and capabilities or suitable for commercialization through Amarin’s current and planned commercial infrastructure in the United States and Europe.

Commercialization synergies with Amarin are likely most applicable for products that are promoted to cardiologists, endocrinologists and primary care physicians. Amarin’s commercial team has demonstrated success communicating scientifically sophisticated messaging and Amarin’s medical affairs team is proven in supporting medical education of scientific breakthroughs. Product opportunities will be most attractive in the following areas:

  • Late-stage innovative assets that address significant unmet medical needs
  • Europe and/or U.S.-inclusive opportunities
  • Significant overlap with our target physician customers (e.g., primary care physicians, cardiologists and endocrinologists)
  • Primary care and orphan products will be considered in multiple areas, including:
    • Cardiovascular-metabolic diseases
    • Dyslipidemia
    • Kidney and urinary tract diseases
    • Liver diseases
    • Respiratory diseases
    • Gastrointestinal tract diseases
    • Depression, migraines and certain neurological and psychological diseases

Below is an example of a collaborative partnership that supports our corporate global strategy: